HM Payson & Co’s Sarepta Therapeutics SRPT Stock Holding History

HM Payson & Co’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10	Closed	-$218	–	1170
2026 Q1	$218	Buy	+10	New	+$194	﹤0.01%	1104
2025 Q3	–	Sell	-1,000	Closed	-$17.1K	–	1119
2025 Q2	$17.1K	Hold	1,000	–	–	﹤0.01%	806
2025 Q1	$63.8K	Hold	1,000	–	–	﹤0.01%	604
2024 Q4	$122K	Hold	1,000	–	–	﹤0.01%	504
2024 Q3	$125K	Hold	1,000	–	–	﹤0.01%	498
2024 Q2	$158K	Hold	1,000	–	–	﹤0.01%	440
2024 Q1	$129K	Hold	1,000	–	–	﹤0.01%	471
2023 Q4	$96.4K	Hold	1,000	–	–	﹤0.01%	497
2023 Q3	$121K	Hold	1,000	–	–	﹤0.01%	451
2023 Q2	$115K	Buy	+1,000	New	+$129K	﹤0.01%	456
2021 Q1	–	Sell	-433	Closed	-$74K	–	1191
2020 Q4	$74K	Sell	433 -106	-20%	-$15.7K	﹤0.01%	531
2020 Q3	$76K	Buy	+539	New	+$81.9K	﹤0.01%	489

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

HM Payson & Co's SRPT Position: Q2 2026 in Review

HM Payson & Co sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 10 shares — an estimated $218 sold.

HM Payson & Co first reported a position in SRPT in Q3 2020 and held it in 12 quarters. The position peaked at $158K in Q2 2024. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

HM Payson & Co reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
HM Payson & Co sold 10 Sarepta Therapeutics shares in Q2 2026, an estimated $218.
HM Payson & Co first reported a position in Sarepta Therapeutics in Q3 2020 and held it in 12 quarters.
HM Payson & Co's Sarepta Therapeutics position peaked at $158K in Q2 2024.
324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on HM Payson & Co's 13F filing for Q2 2026, filed 17 Jul 2026.